The Role of α-Synuclein in Neurodegenerative Diseases: From Molecular Pathways in Disease to Therapeutic Approaches

ISSN: 1875-5828 (Online)
ISSN: 1567-2050 (Print)

Volume 12, 10 Issues, 2015

Download PDF Flyer

Current Alzheimer Research

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 38th of 194 in Clinical Neurology
  • 80th of 251 in Neurosciences

Submit Abstracts Online Submit Manuscripts Online

Prof. Debomoy K. Lahiri
Department of Psychiatry, Indiana University School of Medicine
Neuroscience Research Center
Indianapolis, IN 46202

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.796
5 - Year: 3.998

The Role of α-Synuclein in Neurodegenerative Diseases: From Molecular Pathways in Disease to Therapeutic Approaches

Author(s): Al- Mansoori KM, Hasan MY, Al- Hayani A and El- Agnaf OMA

Affiliation: Department of Biochemistry, Faculty of Medicine and Health Science, UAE University, PO Box 17666, Al- Ain, UAE


Parkinson disease (PD) is the second most prevalent neurodegenerative disorder after Alzheimer’s disease (AD). The formation of the cytoplasmic inclusions named “Lewy bodies” in the brain, considered to be a marker for neuronal degeneration in PD and dementia with Lewy bodies. However, Lewy bodies (LBs) are also observed in approximately 60 percent of both sporadic and familial cases with AD. LBs consist of fibrils mainly formed by post-translational modified α-synuclein (α-syn) protein. The modifications can be truncation, phosphorylation, nitration and mono-, di-, ortri-ubiquitination. Development of disease seems to be linked to events that increase the concentration of α-syn or cause its chemical modification, either of which can accelerate α-syn aggregation. Examples of such events include increased copy number of genes, decreased rate of degradation via the proteasome or other proteases, or modified forms of α-syn. As the aggregation of α-syn in the brain has been strongly implicated as a critical step in the development of several neurodegenerative diseases, the current search for disease-modifying drugs is focused on modification of the process of α-syn deposition in the brain. Recently researchers have screened and designed various molecules that are selectively focused on inhibiting or preventing α-syn aggregation and toxicity. Another strategy that has emerged is to target α-syn expression as a potential therapy for neurodegenerative diseases associated with LBs.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 10
First Page: 1
Page Count: 1
DOI: 10.2174/15672050113109990139

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science